Lucid Diagnostics Inc. LUCD
- Market cap
- $170.3M
- P/E
- 0.0×
Follow LUCD
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 4.61 | 1.15 | 1.04 | 0.63 | 0.78 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 13.52 | 5.53 | 1.85 | 1.58 | 1.80 |
High Price
|
|||
| — | — | — | — | — | — | 74 | 70 | 72 | 82 |
Employees
|
|||
| — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | 1 | 0 | 2 | 4 | 5 |
Revenue
|
|||
| — | — | — | — | — | (17.00%) | (858.62%) | (146.25%) | (63.35%) | (41.73%) |
Gross Margin
|
|||
| — | — | (1) | (4) | (8) | (28) | (56) | (53) | (46) | (58) |
EBT
|
|||
| — | — | 0.00% | 0.00% | 0.00% | (5,615.60%) | (14,899.47%) | (2,169.11%) | (1,047.61%) | (1,232.68%) |
EBT Margin
|
|||
| — | 0 | (1) | (4) | (8) | (28) | (56) | (53) | (46) | (58) |
Net Income
|
|||
| — | — | — | — | — | 0 | 2 | 2 | 1 | 1 |
Depreciation
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.06 | 0.09 | 0.05 |
Revenue/Sh
|
|||
| — | — | (0.03) | (0.12) | (0.59) | (1.51) | (1.55) | (1.26) | (1.05) | (0.69) |
Earnings/Sh
|
|||
| — | — | 0.00 | (0.06) | (0.40) | (0.95) | (0.82) | (0.79) | (0.87) | (0.46) |
Cash Flow/Sh
|
|||
| — | — | 0.00 | 0.00 | 0.00 | (0.05) | (0.03) | (0.01) | (0.01) | 0.00 |
Capex/Sh
|
|||
| — | — | 0.00 | (0.06) | (0.40) | (1.00) | (0.85) | (0.79) | (0.89) | (0.46) |
Free CF/Sh
|
|||
| — | — | (0.03) | (0.14) | (0.96) | 2.94 | 0.64 | (0.06) | 0.11 | 0.11 |
Book Value/Sh
|
|||
| — | — | 37 | 37 | 14 | 19 | 36 | 42 | 51 | 102 |
Shares
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | 0.00 | 74.27 | 23.90 | 9.53 | 23.61 |
PS Ratio
|
|||
| — | — | — | — | — | 1.83 | 2.18 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | — | 0.00 | 42.49 | 21.87 | 8.67 | 21.34 |
EV/Sales
|
|||
| — | — | — | — | — | (3.70) | (0.94) | (1.61) | (0.85) | (2.15) |
EV/FCF
|
|||
| — | — | 0 | (2) | (6) | (18) | (30) | (33) | (44) | (46) |
Op' Cash Flow
|
|||
| — | — | — | — | — | (1) | (1) | 0 | (1) | 0 |
Capex
|
|||
| — | — | 0 | (2) | (6) | (19) | (31) | (33) | (45) | (47) |
FCF
|
|||
| — | — | (1) | (6) | (14) | 53 | 16 | (7) | 2 | 9 |
Working Cap'
|
|||
| — | — | — | — | — | — | 1 | 14 | 19 | 24 |
Total Debt
|
|||
| — | — | 0 | 0 | 0 | (54) | (22) | (5) | (4) | (11) |
Net Debt
|
|||
| — | — | (1) | (5) | (14) | 55 | 23 | (2) | 5 | 11 |
Sh' Equity
|
|||
| — | — | (12,650.56%) | (840.64%) | (512.87%) | (91.77%) | (122.77%) | (176.20%) | (182.89%) | (198.34%) |
ROA
|
|||
| — | — | 0.00% | 0.00% | 0.00% | (1,582.35%) | (2,290.35%) | 0.00% | (1,762.55%) | (13,430.74%) |
ROIC
|
|||
| — | — | 35.34% | 138.75% | 87.96% | (136.23%) | (144.42%) | (4,989.67%) | 151.58% | 152.80% |
ROE
|
|||
Lucid Diagnostics Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| QSI Quantum-Si Incorporated | $172.9M | 0.0× | Compare |
| QTRX Quanterix Corporation | $150.4M | 0.0× | Compare |
| OWLT Owlet, Inc. | $148.2M | 0.0× | Compare |
| RXST RxSight, Inc. | $196.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PROF Profound Medical | $204.6M | 0.0× | Compare |
| INGN Inogen, Inc | $138.8M | 0.0× | Compare |
| STIM Neuronetics, Inc. | $214.9M | 0.0× | Compare |
| ELMD Electromed, Inc. | $233.1M | 20.4× | Compare |
Lucid Diagnostics Inc. (LUCD) key facts
- Lucid Diagnostics Inc. (LUCD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024.
- As of September 25, 2026, LUCD traded at $0.83, a market capitalization of $170.3 million.
- Return on equity was 152.8% and debt-to-equity 2.15.
Lucid Diagnostics Inc. (LUCD) Latest News
22 Sep
Lucid Diagnostics announced advances in payment, billing and coding for EsoGuard and EsoCheck following three public meetings. CMS advised maintaining the original gapfill CLFS payment for EsoGuard (PLA code 0114U). AMA’s CPT Editorial Panel added a Category III code for nonendoscopic esophageal cell collection with EsoCheck, enabling tracking of utilization and outcomes. CDC/NCHS considered a proposed ICD-10-CM code (R85.83) to report positive EsoGuard results to support the rationale for confirmatory endoscopy. The company expects final determinations in November and plans to begin submitting Medicare claims under 0114U for tests at its California lab after a revised LCD, and for its Texas lab in a MAC jurisdiction not participating in MolDX. Lucid says the meetings mark important milestones toward broader access for Medicare beneficiaries. Advances in reimbursement pathways and coding for EsoGuard/EsoCheck improve payer access and potential utilization, supporting revenue growth but not constituting a fundamental business transformation.
20 Aug
Lucid Diagnostics Inc. released its Q2 2026 earnings call transcript covering financial results, operational updates, and strategic outlook for the period. Quarterly earnings details and guidance can moderately shift near-term investor sentiment and stock valuation.
15 Aug
Lucid Diagnostics anticipates Medicare coverage decision as catalyst to accelerate EsoGuard esophageal cell collection device commercialization, adoption and revenue growth. Medicare reimbursement approval would enable broad EsoGuard adoption and drive major revenue growth.
14 Aug
PAVmed Inc. released Q2 2026 earnings call summary covering financial results and operations tied to subsidiary Lucid Diagnostics Inc. (LUCD). Parent company earnings update supplies operational and financial details that moderately shape Lucid Diagnostics outlook.
PAVmed released second quarter 2026 financial results and a business update covering Lucid Diagnostics operations. Parent company earnings and updates deliver moderate operational and sentiment effects on LUCD without altering core trajectory.
13 Aug
Lucid Diagnostics Inc (LUCD) highlighted its strategic pivot to high-value opportunities in the Q2 2026 earnings call. Strategic pivot to high-value areas represents major move that could significantly alter company trajectory.
Lucid Diagnostics Inc. summarized Q2 2026 earnings call covering financial results and outlook. Earnings call delivers updates on financials and strategy with moderate market effects.
Lucid Diagnostics Inc. reported Q2 results in its earnings call, covering financial performance, operational updates and strategic outlook for the company. Q2 earnings provide financial and operational updates that moderately influence near-term stock sentiment and company trajectory.
Lucid Diagnostics Inc. issued a business update and reported second quarter 2026 financial results. Quarterly financial results and business updates routinely affect near-term market perception of performance.
5 Aug
Lucid Diagnostics secures commercial coverage policy spanning multiple health plans for EsoGuard esophageal DNA test. Coverage from multiple health plans expands patient access to EsoGuard and supports revenue growth.
15 May
PAVmed issued a business update on portfolio progress, including Lucid Diagnostics advancements, and reported first quarter 2026 financial results with revenue details and operational highlights. Parent company's quarterly financial results and business update reveal significant operational milestones and financial health directly impacting Lucid Diagnostics' trajectory and investor sentiment.
14 May
Lucid Diagnostics Inc. (LUCD) exceeded test targets in Q1 2026 earnings call highlights, signaling strong performance amid ongoing growth initiatives. Exceeding test targets indicates robust product adoption and operational momentum, likely driving significant positive shifts in financial trajectory and investor sentiment.
Lucid Diagnostics Inc. released Q1 2026 earnings call summary detailing first-quarter financial results, operational updates, and forward guidance. Q1 2026 earnings call summary discloses financial performance and strategic outlook, likely driving significant shifts in investor sentiment and stock trajectory.
Lucid Diagnostics Inc. (LUCD) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript provides key financial metrics, strategic insights, and outlook that can significantly sway LUCD's trajectory and market performance.
Lucid Diagnostics Inc. (LUCD) released Q1 earnings call highlights detailing financial results, operational progress, and strategic outlook. Q1 earnings call highlights provide major updates on financial performance and strategic direction significantly influencing LUCD's trajectory and investor sentiment.
Lucid Diagnostics Inc. (LUCD) provided a business update and reported first quarter 2026 financial results. Quarterly financial results and business update disclosure likely to significantly impact investor sentiment and stock trajectory.
Lucid Diagnostics Inc. (LUCD) reported a Q1 loss and missed revenue estimates. Q1 loss and revenue shortfall indicate weaker-than-expected financial performance, likely affecting investor sentiment and stock price moderately.
24 Apr
Lucid Diagnostics Inc. closed an $18 million underwritten public offering of 13.6 million shares of common stock priced at $1.325 per share, with proceeds intended for general corporate purposes and working capital. Raising $18 million via stock offering bolsters financial runway and enables sustained operations amid cash needs.
23 Apr
Lucid Diagnostics Inc. (LUCD) announced an $18 million underwritten public offering of its common stock, priced at $1.25 per share, with underwriters granted a 45-day option to purchase additional shares. $18 million stock offering provides essential funding for operations amid cash needs but dilutes shareholders and pressures stock price.
30 Mar
PAVmed provided a business update and reported fourth quarter and full-year 2025 financial results, covering operations including subsidiary Lucid Diagnostics. Parent company PAVmed's financial results and business update represent major disclosures likely to drive significant shifts in LUCD's market sentiment and trajectory.
26 Mar
Lucid Diagnostics Inc. (LUCD) reported strong test volume growth in Q4 2025 earnings call highlights. Strong test volume growth demonstrates robust operational momentum and potential revenue acceleration for future performance.
Lucid Diagnostics Inc. Q4 2025 earnings call summary covers financial results, operational updates, and forward guidance for the cancer diagnostics firm. Q4 earnings call summary discloses financial performance and strategic outlook capable of significantly swaying investor sentiment and stock trajectory.
Lucid Diagnostics Inc. (LUCD) released Q4 earnings call highlights detailing financial results, operational progress, strategic initiatives, and forward guidance. Q4 earnings call highlights disclose critical financial outcomes and strategic plans poised to significantly shape LUCD's trajectory and investor outlook.
Lucid Diagnostics Inc. (LUCD) released its earnings call transcript detailing quarterly financial results, operational updates, management discussion, and forward-looking guidance. Earnings transcripts reveal key financial metrics, strategic plans, and guidance that significantly influence stock performance and investor sentiment.
Lucid Diagnostics Inc. (LUCD) provided a business update and reported fourth quarter and full-year 2025 financial results. Reporting Q4 and full-year financial results directly impacts financial performance, investor sentiment, and stock trajectory.
Lucid Diagnostics Inc. (LUCD) reported a Q4 net loss but beat revenue estimates. Q4 revenue beat despite loss affects short-term financial sentiment and operational outlook.
4 Feb
PAVmed has successfully closed financings involving preferred stock and senior secured notes, which has allowed the company to eliminate all previously outstanding convertible securities. This move is expected to strengthen PAVmed's financial position and simplify its capital structure. Eliminating convertible securities may improve financial stability and investor confidence, but the overall impact on Lucid Diagnostics' trajectory is expected to be limited.
21 Jan
Lucid Diagnostics Inc. has been awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard® test, which is designed to detect esophageal precancer and cancer. This contract will enable the VA to provide EsoGuard® testing to veterans, potentially improving early detection and treatment options for esophageal conditions. The partnership is expected to enhance Lucid's market presence and support its growth strategy in the healthcare sector. The contract with the U.S. Department of Veterans Affairs represents a significant strategic move that could enhance Lucid's market position and revenue potential.
Lucid Diagnostics Inc. (LUCD) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. This uptick in activity may reflect broader market trends or specific developments related to the company, potentially influencing its stock performance and investor sentiment moving forward. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
9 Jan
Lucid Diagnostics Inc. insider has increased their holdings by 162% over the past year, indicating strong confidence in the company's future prospects. This significant investment by an insider may influence market sentiment and investor perception of the company's potential growth. Insider buying can signal confidence in the company's future, potentially affecting market sentiment and stock performance.